Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics
US biotech major Gilead Sciences (Nasdaq: GILD) has appointed Philippe Bishop as senior vice president of hematology and oncology therapeutics.
He joins from Genentech, a Roche subsidiary (ROG: SIX), where he was vice president of product development in oncology since 2007. Prior to this, he held positions at Johnson & Johnson (NYSE: JNJ) and Sanofi-Aventis (Euronext: SAN). He has also worked at the US Food and Drug Administration and the National Institutes of Health.
John McHutchison, executive vice president of clinical research, said: "Philippe is an accomplished physician with an extensive background in cancer drug development and I am very pleased to welcome him to Gilead. Philippe's appointment reflects Gilead's ongoing commitment to further building a leading hematology and oncology therapeutic area. His clinical development expertise, translational focus and strategic leadership will be of great value as we work to advance our growing pipeline of therapies for hematological malignancies and solid tumors."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze